[D1-A5] Advancing drug development: Comprehensive and optimum approaches to the immunogenicity assessment

5:35 PM - 6:05 PM JST(8:35 AM - 9:05 AM UTC)

[D1-A5-01] Crafting a Science-Driven Immunogenicity Risk Assessment

*Joleen T White¹ (1. Bill & Melinda Gates Medical Research Institute (Gates MRI))

Password required to view

Log in

or